Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Diagnosed with type 2 diabetes mellitus~* HbA1c 7.1 to 11%, inclusive, at screening~* Fasting plasma glucose \<280 mg/dL (15.5 mmol/L)~* Body mass index (BMI) \<=45 kg/m2, inclusive, at screening~* Treated with diet and exercise or a stable regimen of metformin, sulfonylurea, pioglitazone or any 2 of these agents~Exclusion Criteria:~* History of pancreatitis or triglycerides \>=500 mg/dL~* Medullary carcinoma or multiple endocrine neoplasia (MEN2) or a family history of either~* Active cardiovascular disease~* Presence of congestive heart failure~* Liver disease~* History of severe gastrointestinal diseases~* Repeated severe hypoglycemia within the last 6 months~* Any previous use of exenatide or other glucagon-like peptide-1 (GLP-1 ) analog~* Dipeptidyl peptidase-4 (DPP-4) inhibitor use in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide once weekly suspension (Type: EXPERIMENTAL): Exenatide suspension 2 mg weekly subcutaneous injection
- Exenatide twice daily (BID) (Type: ACTIVE_COMPARATOR): Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).